Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial.

Publication date: Dec 14, 2024

To identify demographic, clinical and immunological factors associated with adverse COVID-19 outcomes. A large randomised controlled trial of ChAdOx1 nCoV-19 was undertaken in Brazil. Participants were randomised 1:1 either to receive ChAdOx1 nCov-19 or to a control group. COVID-19 infections were confirmed by nucleic acid amplification test (NAAT) and classified using the WHO clinical progression scale. Anti-spike antibody responses and serum neutralising activity were measured 28 days after second vaccination in some participants. Exploratory analyses were conducted into factors associated with COVID-19 infection severity and hospitalisation, using logistic regression models adjusted for demographic and clinical factors. 10,416 participants were enrolled; 1790 had NAAT-positive COVID-19 infection; 63 cases required hospitalisation. More severe infection was associated with greater body-mass index (BMI) (odds ratio [OR] = 1. 06 [95 %CI: 1. 01-1. 10], p = 0. 01) and diabetes (OR = 3. 67 [1. 59-8. 07], p = 0. 003). Hospitalisation risk increased with greater age (OR = 1. 06 [1. 03-1. 08], p

Open Access PDF

Concepts Keywords
28days Coronavirus
Brazil Epidemiology
Diabetes Immunisation
Randomised Pandemic
Vaccination Vaccine effectiveness

Semantics

Type Source Name
disease MESH SARS-CoV-2 infections
disease MESH infections
disease IDO nucleic acid
disease MESH clinical progression
disease IDO infection
disease MESH Long Covid

Original Article

(Visited 1 times, 1 visits today)